Researchers at the National Cancer Institute (NCI) seek research collaborations or licensees for a monoclonal antibody targeting TEM8 and related conjugates. The antibody and antibody drug conjugates (ADC) containing the antibody of the current invention were tested in vivo and have potential for use in cancer immunotherapy.
Chimeric Antigen Receptor T cell (CAR-T) therapies that specifically target B-cell maturation antigen (BCMA) are strong therapeutic candidates for patients with plasma cell malignancy diseases such as, multiple myeloma (MM), as well as for patients with Hodgkin’s lymphoma. BCMA is a cell surface protein preferentially expressed on a subset of B cells and mature plasma cells, but not on other cells in the body. The limited expression of BCMA on B and plasma cells makes BCMA an attractive therapeutic target for B cell and plasma cell malignancy diseases. The 12 anti-BCMA CARs described are fully human CARS and have the potential to treat patients with various plasma cell and B cell malignancy diseases.
Researchers at the National Cancer Institute (NCI) have developed nucleic-acid-based nanoparticle that can be adapted for RNA interference (RNAi), molecular imaging, or a combination thereof. The invention nanoparticles can be used as therapeutics in the treatment of cancer, whichthe NCI seeks parties to license or co-develop.
Novel fusion proteins with good stability and potency against HIV-1. These fusion proteins have good drug properties and potential as prophylactics or therapeutics against HIV-1 infection. Researchers at the NCI seek licensing for the development and commercialization of novel fusion proteins as therapeutics or prophylactics against HIV-1 infection.
GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). NICHD seeks parties to license this invention towards commercialization.
There is a marked increase in immunosuppressive myeloid progenitors and myeloid cells in tumors and at metastatic tissue sites, rendering these types of cells useful in cancer therapeutics, especially after genetic modifications that improve their anti-tumor properties further. The National Cancer Institute (NCI) seeks research co-development or licensing partners to further develop genetically engineered myeloid cells (GEMys) for use in cancer immunotherapy.
Scientists at the National Cancer Institute's Molecular Targets Laboratory have modified the Cnidarin-derived griffithsin compound to have greater storage time and stability. Griffithsin compounds are a class of highly potent proteins capable of blocking the HIV virus from penetrating T cells. The National Cancer Institute seeks parties interested in collaborative research to license or co-develop large-scale recombinant production of the compound.
The National Cancer Institute’s Laboratory of Experimental Immunology seeks partners interested in licensing or collaborative research to co-develop monoclonal antibodies and ADCs, and methods of making them.
Researchers at the National Cancer Institute (NCI) have isolated two high affinity anti-mesothelin single domain antibodies (also known as nanobodies), A101 and G8. These antibodies have been isolated from NCI’s newly developed camel single domain (VHH) libraries by phage display. The antibodies have a high affinity for mesothelin-positive tumor cells from both human and mouse origins. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.
Researchers at the National Cancer Institute (NCI) have isolated two Glypican-1- (GPC1)- specific antibodies: the mouse monoclonal antibody HM2 that binds the C-lobe of GPC1 close to the cell surface, and the camel single domain antibody D4. The D4 single domain antibody (also called ‘nanobody’) has a high affinity for GPC1-positive tumor cells from both human and mouse origins. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.
Cancer therapies that specifically target Glypican 2 (GPC2) are strong therapeutic candidates for pediatric patients with neuroblastoma and other GPC2 expressing cancers. The inventors at the National Cancer Institute (NCI) have developed and isolated two new antibodies that target GPC2 (CT3 and CT5) that are available for licensing and co-development.
Researchers at the National Cancer Institute (NCI) have developed an invention reporting the composition and function of a pyrimido-dione-quinoline that was found to inhibit HDM2’s ubiquitin ligase (E3) activity without accompanying genotoxicity. The current invention results in the stabilization of p53 in cells through the inhibition of its ubiquitin-mediated proteasomal degradation resulting in a robust p53 response in tumors. NCI researchers seek licensing and/or co-development partners for this invention.
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.
Researchers at NCI's Cancer and Inflammation Program developed fully human monoclonal antibodies that bind and neutralize dengue type 1, 2, 3 and 4 viruses. The National Cancer Institute's Cancer and Inflammation Program seeks parties interested in licensing fully human monoclonal antibodies as possible therapeutics and prophylactics, as well as a template for a Dengue vaccine.
The National Cancer Institute's Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing monoclonal antibodies to IGF-1 and IGF-II for the treatment of cancer.